Filing Flows › Sanuwave Health (SNWV) › Q1 2025
Sanuwave Health (SNWV) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Sanuwave Health (SNWV) reported revenue of $9.3M for the first quarter 2025 (Q1 2025), +61% from a year earlier and -10% from the quarter before. Operating margin was 10.6%, net loss $5.7M (60.8% of revenue).
Sanuwave Health, Q1 2025: revenue $9.3M (+61% year over year), operating margin 10.6%, net loss $5.7M, operating cash flow −$1.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.3M | -10% | +61% |
| Operating profit | $986K | -61% | — |
| Net earnings | −$5.7M | — | — |
| Operating cash flow | −$1.5M | -305% | — |
What changed
Revenue was $9.3M in Q1 2025, up 61% year over year and down 10% from the previous quarter. Consumables and parts revenue was the largest line at 65% of revenue. System revenue added $1.8M year over year (up 133%), 51% of the total change.
Gross margin was 79.0%, up 6.4 points from a year earlier. Operating profit was $1.0M, a 10.6% margin (up 28.7 points year over year). Operating expenses grew 22% against revenue growth of 61%. The fastest-growing cost line was Research & development (+28%). The quarter ended with a net loss of $5.7M, narrower than the previous quarter's $12.7M loss. Net interest and other expense of $6.7M was the main reason.
Operating cash flow was −$1.5M. Non-cash charges added back $209K of depreciation and amortization and $1.0M of share-based compensation. Working capital and other items added $3.0M. Capital expenditures of $162K exceeded it, leaving free cash flow of −$1.7M.
Questions
What was Sanuwave Health's revenue in the first quarter 2025?
Sanuwave Health (SNWV) reported revenue of $9.3M for the first quarter 2025 (Q1 2025), +61% from a year earlier and -10% from the quarter before.
Was Sanuwave Health profitable in the first quarter 2025?
Operating profit was $986K (10.6% of revenue) and net loss $5.7M.
Source: Sanuwave Health 10-Q on SEC EDGAR.